DBV Technologies (DBVT) Total Non-Current Liabilities (2015 - 2026)
DBV Technologies (DBVT) reported Total Non-Current Liabilities of $6.7 million for Q1 2026, down 8.28% year-over-year from $7.3 million in Q1 2025, and down 2.9% quarter-over-quarter from $6.9 million in Q4 2025.
DBV Technologies (DBVT) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 12 years of Total Non-Current Liabilities data on file, last reported at $6.7 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $6.7 million, down 8.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.7 million (down 8.28% YoY), and the FY2025 annual result was $6.9 million, down 3.29% from the prior year.
- Total Non-Current Liabilities slipped to $6.7 million in Q1 2026 per DBVT's latest filing, from $6.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $22.5 million in Q4 2022 and troughed at $5.5 million in Q4 2023.
- A 5-year average of $10.5 million and a median of $7.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 121.92% in 2023 and fell as far as 75.78% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $22.5 million in 2022, then plunged by 75.78% to $5.5 million in 2023, then surged by 30.65% to $7.1 million in 2024, then slipped by 3.29% to $6.9 million in 2025, then slipped by 2.9% to $6.7 million in 2026.
- Business Quant data shows DBVT's Total Non-Current Liabilities at $6.7 million in Q1 2026, $6.9 million in Q4 2025, and $8.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 6.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.70 Mn |
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 8.16 Mn |
| Jun 30, 2025 | 7.78 Mn |
| Mar 31, 2025 | 7.31 Mn |
| Dec 31, 2024 | 7.14 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Jun 30, 2024 | 7.71 Mn |
| Mar 31, 2024 | 7.76 Mn |
| Dec 31, 2023 | 5.46 Mn |
| Sep 30, 2023 | 14.35 Mn |
| Jun 30, 2023 | 19.91 Mn |
| Mar 31, 2023 | 21.06 Mn |
| Dec 31, 2022 | 22.54 Mn |
| Sep 30, 2022 | 7.67 Mn |
| Jun 30, 2022 | 10.13 Mn |
| Mar 31, 2022 | 9.49 Mn |
| Dec 31, 2021 | 16.05 Mn |
| Sep 30, 2021 | 20.22 Mn |
| Jun 30, 2021 | 18.87 Mn |